Abstract
Alpha-methyl-para-tyrosine (AMPT) temporarily inhibits tyrosine hydroxylase, the rate limiting step in the dopamine biosynthesis cascade. AMPT has been approved for clinical use in phaeochromocytoma in 1979. Recently however, AMPT has been increasingly employed as a pharmacological challenge in acute dopamine depletion studies including neuroimaging studies. The use of this exciting challenge technique allows us to increase our understanding of dopaminergic neurotransmission in the brain. In addition, there have been clinical reports that AMPT may be useful to treat movement disorders like dystonia, dyskinesia and Huntingtons chorea, psychiatric disorders like mania, psychosis, obsessive compulsive disorder and substance abuse as well as behavioral problems in 22q11 deletion syndrome. In this review we will discuss the effects of AMPT in challenge studies that have been reported in humans. Furthermore we will review all studies reporting therapeutic effects of AMPT in neuropsychiatric disorders and adverse effects associated with AMPT use reported in both challenge and therapeutic research.
Keywords: Alpha-methyl-para-tyrosine, AMPT, dopamine, depletion, challenge, treatment, catecholamine
Central Nervous System Agents in Medicinal Chemistry
Title: Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review
Volume: 8 Issue: 4
Author(s): Oswald J.N. Bloemen, M. B. de Koning, E. Boot, J. Booij and T.A. M.J. van Amelsvoort
Affiliation:
Keywords: Alpha-methyl-para-tyrosine, AMPT, dopamine, depletion, challenge, treatment, catecholamine
Abstract: Alpha-methyl-para-tyrosine (AMPT) temporarily inhibits tyrosine hydroxylase, the rate limiting step in the dopamine biosynthesis cascade. AMPT has been approved for clinical use in phaeochromocytoma in 1979. Recently however, AMPT has been increasingly employed as a pharmacological challenge in acute dopamine depletion studies including neuroimaging studies. The use of this exciting challenge technique allows us to increase our understanding of dopaminergic neurotransmission in the brain. In addition, there have been clinical reports that AMPT may be useful to treat movement disorders like dystonia, dyskinesia and Huntingtons chorea, psychiatric disorders like mania, psychosis, obsessive compulsive disorder and substance abuse as well as behavioral problems in 22q11 deletion syndrome. In this review we will discuss the effects of AMPT in challenge studies that have been reported in humans. Furthermore we will review all studies reporting therapeutic effects of AMPT in neuropsychiatric disorders and adverse effects associated with AMPT use reported in both challenge and therapeutic research.
Export Options
About this article
Cite this article as:
Bloemen J.N. Oswald, de Koning B. M., Boot E., Booij J. and van Amelsvoort M.J. T.A., Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (4) . https://dx.doi.org/10.2174/187152408786848102
DOI https://dx.doi.org/10.2174/187152408786848102 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design Exploring the Effectiveness of Acupuncture as an Adjunct to Physiotherapy in the Treatment of Musculoskeletal Conditions: A Systematic Review
New Emirates Medical Journal Safety and Efficacy of Dexamethasone Intravitreal Implant (Ozurdex) for the Treatment of Persistent Macular Edema Secondary to Retinal Vein Occlusion in Eyes Previously Treated with Anti-Vascular Endothelial Growth Factors
Current Drug Safety The HIV Entry Inhibitors Revisited
Current Medicinal Chemistry Paracrine Provision of Lipids in the Immune System
Current Immunology Reviews (Discontinued) Defining a Role for Mucosal Immunity in the Prevention and Pathogenesis of Respiratory Allergic Diseases
Current Immunology Reviews (Discontinued) Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypertension in Pregnancy: Clinical Manifestations and Treatment
Current Hypertension Reviews Evaluation of Arthritis in Hanseniase
Current Rheumatology Reviews Conference Report (42nd Annual Meeting of the Italian Society of Neurology, 22-25 October 2011, Turin, Italy)
CNS & Neurological Disorders - Drug Targets Alternative Gene Therapy Strategies for the Repair of Craniofacial Bone Defects
Current Gene Therapy Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art
Current Drug Targets CXCR4-CXCL12-Dependent Inflammatory Network and Endothelial Progenitors
Current Medicinal Chemistry Electroporation: An Effective Method For <i>In Vivo</i> Gene Delivery
Drug Delivery Letters Physical Work and Exercise Reduce the Risk of Cognitive Impairment in Older Adults: A Population-based Longitudinal Study
Current Alzheimer Research Do Human Lipoxygenases have a PDZ Regulatory Domain?
Current Molecular Medicine Computational Peptidology: A New and Promising Approach to Therapeutic Peptide Design
Current Medicinal Chemistry Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia
Current Pharmaceutical Design Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Central Nervous System Agents in Medicinal Chemistry